Picture of Cell MedX logo

CMXC Cell MedX Income Statement

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro CapValue Trap

Annual income statement for Cell MedX, fiscal year end - May 31st, USD millions except per share, conversion factor applied.

2020
May 31st
2021
May 31st
2022
May 31st
2023
May 31st
2024
May 31st
Period Length:12 M12 M12 M12 M12 M
Source:10-K10-K10-K10-K10-K
Standards:
USG
USG
USG
USG
USG
Status:FinalFinalFinalFinalFinal
Revenue
Total Revenue0.0960.0070.0060.0030
Cost of Revenue
Gross Profit0.0860.0040.00400
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses1.130.7320.6780.450.081
Operating Profit-1.04-0.725-0.672-0.448-0.081
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes-1.09-0.911-0.697-0.495-0.142
Net Income After Taxes-1.09-0.911-0.697-0.495-0.142
Net Income Before Extraordinary Items
Net Income-1.09-0.911-0.697-0.495-0.142
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income-1.09-0.911-0.697-0.495-0.142
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS-0.022-0.012-0.011-0.008-0.002